Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Incyte’s latest 10-K means sifting through pages of clinical-trial data, FDA milestones, and royalty tables—details that can obscure crucial signals like how much Jakafi revenue offsets soaring R&D costs. If finding Incyte insider trading Form 4 transactions before a pivotal read-out feels daunting, you’re not alone.
Stock Titan’s AI reads every Incyte quarterly earnings report 10-Q filing, 8-K material events explained, and the full Incyte annual report 10-K simplified so you don’t have to. Our platform delivers real-time alerts the moment an Incyte Form 4 insider transactions real-time notice posts to EDGAR, then translates legal jargon into plain English. Need a quick brief on trial spend vs. cash reserves? Our AI-powered summaries surface it in one click, making understanding Incyte SEC documents with AI part of your routine.
Use the filing types below to answer the questions professionals ask every quarter:
- 10-Q: Track segment revenue, pipeline spend, and compare results with our Incyte earnings report filing analysis.
- 10-K: Review patent cliffs, market-size assumptions, and risk factors—Incyte SEC filings explained simply.
- Form 4: Monitor Incyte executive stock transactions Form 4 for buying or selling patterns.
- DEF 14A: See the Incyte proxy statement executive compensation section without hunting through tables.
- 8-K: Get Incyte 8-K material events explained within minutes of release.
Whether you’re gauging partnership royalty streams or confirming cash runway, Stock Titan turns dense biotech disclosures into actionable knowledge—before the market reacts.
In its Form 8-K dated June 26, 2025, Incyte Corporation (INCY) disclosed a major leadership transition.
Retirement of CEO Hervé Hoppenot: Mr. Hoppenot stepped down as President & Chief Executive Officer effective June 26, 2025, but will remain on the Board and act as special advisor for up to one year. Compensation during the advisory period equals his current $1,395,731 annual base salary for six months and 50% of that rate for the subsequent six months, plus a prorated 2025 cash bonus. He also received equity grants of 6,016 RSUs, 18,438 stock options, and 18,050 performance shares (0-200% payout, 3-year TSR goals), all of which will continue to vest post-transition, subject to customary covenants.
Appointment of William J. Meury as President & CEO: Effective the same date, Mr. Meury (age 57) joins the company and its Board. His background includes CEO roles at Anthos Therapeutics (2024-2025) and Karuna Therapeutics (2023-2024), senior commercial leadership at Allergan, and over 30 years in biopharma commercialization.
Compensation package for Mr. Meury: • Initial base salary $1,250,000 • Target annual bonus 100% of salary (pro-rated for 2025) • Time-based RSUs for 36,101 shares (25% per year over four years) • Options for 110,630 shares (25% after one year, then monthly over 36 months) • 108,303 performance shares (0-200% payout, 3-year TSR goals) • One-time sign-on PSU award for 125,000 shares (0-400% payout tied to multi-year stock-price hurdles) • Relocation and commuting benefits. Severance terms include 1.5× salary+target bonus if terminated without Cause or he resigns for Good Reason outside a change-of-control window, plus partial accelerated vesting of equity.
Governance changes: Lead Independent Director Julian C. Baker becomes Chairman of the Board.
These actions signal a planned but material shift in senior leadership, accompanied by significant equity-based incentives designed to align the incoming CEO with long-term shareholder value.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
What is Incyte Corp's primary focus?
How does Incyte generate revenue?
What therapeutic areas does Incyte primarily target?
How does Incyte differentiate itself in the competitive biopharmaceutical industry?
What is unique about Incyte's drug development approach?
Can you explain Incyte's role in addressing unmet medical needs?
What are some of the key products in Incyte's portfolio?
What role do strategic partnerships play at Incyte?
